MFAP4 as a novel biomarker for predicting liver fibrosis and prognosis in infants with biliary atresia through the integration of bioinformatics with clinical data analysis

BackgroundBiliary atresia (BA) is a progressive obliteration of intrahepatic and extrahepatic bile ducts. Our study aimed to identify and validate hub genes that are differentially expressed in BA, and to investigate their relationship with liver fibrosis.MethodsThe BA microarray datasets GSE46960 a...

Full description

Saved in:
Bibliographic Details
Main Authors: Chunxiao Yang, Jianghua Zhan
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Pediatrics
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2025.1611564/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850125041519296512
author Chunxiao Yang
Chunxiao Yang
Jianghua Zhan
Jianghua Zhan
author_facet Chunxiao Yang
Chunxiao Yang
Jianghua Zhan
Jianghua Zhan
author_sort Chunxiao Yang
collection DOAJ
description BackgroundBiliary atresia (BA) is a progressive obliteration of intrahepatic and extrahepatic bile ducts. Our study aimed to identify and validate hub genes that are differentially expressed in BA, and to investigate their relationship with liver fibrosis.MethodsThe BA microarray datasets GSE46960 and GSE15235 were downloaded from the Gene Expression Omnibus (GEO) database. Clinical BA liver tissue samples were collected for quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blotting (WB). Serum samples were analyzed for MFAP4 content using enzyme-linked immunosorbent assay (ELISA), and the corresponding clinical data of pediatric patients were collected. The relationship between serum MFAP4 levels and liver fibrosis, as well as prognosis, was investigated using ROC curve analysis. Furthermore, Kaplan–Meier (KM) curves were used to validate the prognostic significance of MFAP4 levels.ResultsThrough bioinformatics analysis and experimental validation, MFAP4 was identified as a hub gene. MFAP4 via PCR and immunohistochemistry is significantly upregulated in biliary atresia compared to total functional cyst liver tissue. Serum MFAP4 levels accurately reflects the degree of liver fibrosis in patients with BA. High serum MFAP4 levels predicted a poorer native liver survival rate one year after Kasai surgery.ConclusionsWe discovered that MFAP4 is a crucial BA-associated gene, and validated its expression in BA. Furthermore, serum MFAP4 levels may serve as predictive markers for the degree of liver fibrosis and autologous liver survival after Kasai surgery.
format Article
id doaj-art-a492912b7f754d9cb366be44d242250c
institution OA Journals
issn 2296-2360
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pediatrics
spelling doaj-art-a492912b7f754d9cb366be44d242250c2025-08-20T02:34:12ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602025-05-011310.3389/fped.2025.16115641611564MFAP4 as a novel biomarker for predicting liver fibrosis and prognosis in infants with biliary atresia through the integration of bioinformatics with clinical data analysisChunxiao Yang0Chunxiao Yang1Jianghua Zhan2Jianghua Zhan3Graduate College, Tianjin Medical University, Tianjin, ChinaDepartment of General Surgery, Zibo Municipal Hospital, Shandong, ChinaGraduate College, Tianjin Medical University, Tianjin, ChinaDepartment of General Surgery, Tianjin Children’s Hospital, Tianjin, ChinaBackgroundBiliary atresia (BA) is a progressive obliteration of intrahepatic and extrahepatic bile ducts. Our study aimed to identify and validate hub genes that are differentially expressed in BA, and to investigate their relationship with liver fibrosis.MethodsThe BA microarray datasets GSE46960 and GSE15235 were downloaded from the Gene Expression Omnibus (GEO) database. Clinical BA liver tissue samples were collected for quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blotting (WB). Serum samples were analyzed for MFAP4 content using enzyme-linked immunosorbent assay (ELISA), and the corresponding clinical data of pediatric patients were collected. The relationship between serum MFAP4 levels and liver fibrosis, as well as prognosis, was investigated using ROC curve analysis. Furthermore, Kaplan–Meier (KM) curves were used to validate the prognostic significance of MFAP4 levels.ResultsThrough bioinformatics analysis and experimental validation, MFAP4 was identified as a hub gene. MFAP4 via PCR and immunohistochemistry is significantly upregulated in biliary atresia compared to total functional cyst liver tissue. Serum MFAP4 levels accurately reflects the degree of liver fibrosis in patients with BA. High serum MFAP4 levels predicted a poorer native liver survival rate one year after Kasai surgery.ConclusionsWe discovered that MFAP4 is a crucial BA-associated gene, and validated its expression in BA. Furthermore, serum MFAP4 levels may serve as predictive markers for the degree of liver fibrosis and autologous liver survival after Kasai surgery.https://www.frontiersin.org/articles/10.3389/fped.2025.1611564/fullbiliary atresialiver fibrosisMFAP4immunohistochemistryPCR
spellingShingle Chunxiao Yang
Chunxiao Yang
Jianghua Zhan
Jianghua Zhan
MFAP4 as a novel biomarker for predicting liver fibrosis and prognosis in infants with biliary atresia through the integration of bioinformatics with clinical data analysis
Frontiers in Pediatrics
biliary atresia
liver fibrosis
MFAP4
immunohistochemistry
PCR
title MFAP4 as a novel biomarker for predicting liver fibrosis and prognosis in infants with biliary atresia through the integration of bioinformatics with clinical data analysis
title_full MFAP4 as a novel biomarker for predicting liver fibrosis and prognosis in infants with biliary atresia through the integration of bioinformatics with clinical data analysis
title_fullStr MFAP4 as a novel biomarker for predicting liver fibrosis and prognosis in infants with biliary atresia through the integration of bioinformatics with clinical data analysis
title_full_unstemmed MFAP4 as a novel biomarker for predicting liver fibrosis and prognosis in infants with biliary atresia through the integration of bioinformatics with clinical data analysis
title_short MFAP4 as a novel biomarker for predicting liver fibrosis and prognosis in infants with biliary atresia through the integration of bioinformatics with clinical data analysis
title_sort mfap4 as a novel biomarker for predicting liver fibrosis and prognosis in infants with biliary atresia through the integration of bioinformatics with clinical data analysis
topic biliary atresia
liver fibrosis
MFAP4
immunohistochemistry
PCR
url https://www.frontiersin.org/articles/10.3389/fped.2025.1611564/full
work_keys_str_mv AT chunxiaoyang mfap4asanovelbiomarkerforpredictingliverfibrosisandprognosisininfantswithbiliaryatresiathroughtheintegrationofbioinformaticswithclinicaldataanalysis
AT chunxiaoyang mfap4asanovelbiomarkerforpredictingliverfibrosisandprognosisininfantswithbiliaryatresiathroughtheintegrationofbioinformaticswithclinicaldataanalysis
AT jianghuazhan mfap4asanovelbiomarkerforpredictingliverfibrosisandprognosisininfantswithbiliaryatresiathroughtheintegrationofbioinformaticswithclinicaldataanalysis
AT jianghuazhan mfap4asanovelbiomarkerforpredictingliverfibrosisandprognosisininfantswithbiliaryatresiathroughtheintegrationofbioinformaticswithclinicaldataanalysis